{"id":"ct327-0-5","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting 11β-HSD1, CT327 reduces the conversion of cortisone to cortisol, thereby decreasing inflammation and potentially treating various inflammatory conditions.","oneSentence":"CT327 is a selective inhibitor of the 11β-HSD1 enzyme.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:29:52.957Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT01808157","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis","status":"COMPLETED","sponsor":"Creabilis SA","startDate":"2013-07","conditions":"Atopic Dermatitis","enrollment":188},{"nctId":"NCT01465282","phase":"PHASE2","title":"Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Creabilis SA","startDate":"2011-12","conditions":"Psoriasis Vulgaris","enrollment":160},{"nctId":"NCT01368315","phase":"PHASE1","title":"CT 327 in the \"Atopy Patch Test\" Model","status":"WITHDRAWN","sponsor":"Creabilis SA","startDate":"","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00996008","phase":"PHASE2","title":"CT 327 in the Treatment of Atopic Dermatitis","status":"TERMINATED","sponsor":"Creabilis SA","startDate":"2009-11","conditions":"Mild to Moderate Atopic Dermatitis","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CT327 0.5%","genericName":"CT327 0.5%","companyName":"Creabilis SA","companyId":"creabilis-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CT327 is a selective inhibitor of the 11β-HSD1 enzyme. Used for Treatment of atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}